Last reviewed · How we verify

Methylprednisolone and azathioprine

Xiaoli Fan · FDA-approved active Small molecule Quality 5/100

Methylprednisolone and azathioprine is a Small molecule drug developed by Xiaoli Fan. It is currently FDA-approved.

Methylprednisolone and azathioprine, marketed by Xiaoli Fan, is a combination therapy currently available in the market. The key composition patent is set to expire in 2028, providing a period of exclusivity that supports current market positioning. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic nameMethylprednisolone and azathioprine
SponsorXiaoli Fan
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Methylprednisolone and azathioprine

What is Methylprednisolone and azathioprine?

Methylprednisolone and azathioprine is a Small molecule drug developed by Xiaoli Fan.

Who makes Methylprednisolone and azathioprine?

Methylprednisolone and azathioprine is developed and marketed by Xiaoli Fan (see full Xiaoli Fan pipeline at /company/xiaoli-fan).

What development phase is Methylprednisolone and azathioprine in?

Methylprednisolone and azathioprine is FDA-approved (marketed).

Related